新型冠状病毒（SARS-CoV-2）感染引起了全球出现大量急性新型冠状病毒肺炎（COVID-19）患者，随着病程演变，部分患者在急性期过后出现肺纤维化问题逐渐突显。目前学者们称之为新型冠状病毒感染后肺纤维化（PCPF）。由于SARS-CoV-2不断突变及全球医疗水平大相径庭，PCPF发生率及诊治亦存在差异。肺纤维化程度显著影响患者临床表现，患者症状迁延，需要大量医疗资源及长期的专业照护。目前PCPF诊断依靠临床结合CT及肺功能检查，治疗依靠既往其他肺纤维化疾病的治疗经验，缺乏统一、规范的处置方案。尽管许多学者为此开展研究，但仍没有十分有效的治疗方法。本文就PCPF发病及其机制进行概述，重点回顾相关诊断及治疗研究进展。

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a large number of patients with corona virus disease 2019 (COVID-19) in the world, with the evolution of the disease, the problem of pulmonary fibrosis in some patients after the acute stage has become increasingly prominent. Currently, scholars call it post COVID-19 pulmonary fibrosis (PCPF). Due to the continuous mutation of the virus and different medical levels in different parts of the world, the incidence, diagnosis and treatment of PCPF vary slightly among different studies. The degree of fibrosis significantly affects the clinical manifestations of patients, prolonged symptoms of patients, the need for a large number of medical resources and long-term professional care. At present, the diagnosis of PCPF depends on clinical combination with CT and pulmonary function test (PFT), and the treatment depends on previous treatment experience of other pulmonary fibrosis diseases, and there is a lack of unified and standardized treatment plan. Although many scholars have carried out research for this, there is still no very effective treatment. During this review the pathogenesis and mechanism of PCPF are summarized, and the research progress of related diagnosis and treatment is reviewed.